Business Context and Reporting Period
Company: Bovie Medical Corporation (Ticker: BVX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Bovie is a medical device manufacturer specializing in electrosurgical generators, accessories, battery-operated cauteries, and endoscopic instruments. The company operates through its main U.S. facility in St. Petersburg, Florida, and a Canadian subsidiary (Bovie Canada) focused on product development and manufacturing. In 2007, the company acquired 100% ownership of its J-Plasma joint venture and continued developing new technologies such as the ICON GS plasma system and modular endoscopic instruments.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Net Sales | $28,779,157 | $26,676,182 |
| Gross Profit | $11,315,513 | $10,600,756 |
| Gross Margin | 39.3% | 39.7% |
| Operating Income | $2,106,506 | $2,623,842 |
| Net Income | $2,400,591 | $2,683,206 |
| Diluted EPS | $0.14 | $0.16 |
| Cash and Equivalents | $3,534,759 | $2,952,892 |
| Working Capital | $9,761,008 | $7,955,412 |
| Long-Term Debt | $318,150 | $368,150 |
Note: Debt consists primarily of amounts due to Lican Developments LTD related to asset acquisitions. The company maintains a $1.5 million revolving credit facility with zero funds drawn as of year-end.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.9% to $28.8 million, driven by an 11.1% increase in electrosurgical product sales and a 32.7% surge in international sales (attributed to the declining U.S. dollar and increased IDS product line sales).
- Profitability Decline: Despite revenue growth, Net Income decreased 10.5% to $2.4 million. This was primarily due to a 52.6% increase in Research and Development (R&D) expenses ($1.64 million vs. $1.05 million) and higher professional services costs.
- Cost Structure: Cost of sales remained stable at 60.7% of revenue. However, R&D expenses rose significantly due to costs associated with the new Canadian facility, salary increases, and final testing of the ICON GI device.
- Tax Benefit: The company recorded a significant tax benefit in 2007 due to the reversal of valuation allowances on deferred tax assets (net operating loss carryforwards), which were deemed realizable based on improved profitability trends.
- Customer Concentration: Arthrex, Inc. remained the largest customer, accounting for 21% of total revenues in 2007 (down slightly from 22% in 2006). The top ten customers accounted for 71% of net revenues.
Outlook, Risks, and Management Commentary
- Product Pipeline: Management anticipates growth from new products, specifically the ICON GI platform and the ICON GS J-Plasma device, forecast for completion in the second half of 2008. Development of modular endoscopic instruments (MEG and Polarian handles) is also a key growth driver.
- Strategic Acquisitions: The company acquired 100% of the J-Plasma joint venture in May 2007 for $500,000. It also continues to develop assets acquired from Lican Developments LTD, subject to milestone-based stock payments and royalties.
- Internal Controls: Management identified a significant deficiency in disclosure controls as of December 31, 2007, regarding the initial failure to include required income tax and segment disclosures in financial statements prior to board review. Management states this deficiency has been remediated as of the filing date.
- Risk Factors:
- Customer Concentration: Reliance on Arthrex (21% of sales) poses a risk if orders are reduced or ceased.
- Regulatory: Products are subject to FDA and international regulations; failure to obtain clearance for new products could delay revenue.
- Intellectual Property: Potential litigation regarding J-Plasma technology with a former licensee (Soring) exists, though no material litigation is currently outstanding.
- Weather: Manufacturing facilities in Florida are exposed to hurricane risks.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the relationship with Arthrex, Inc., which represents over 20% of revenue.
- R&D ROI: Assess the timeline and commercial viability of the ICON GS J-Plasma and modular endoscopic instruments, given the sharp increase in R&D spend.
- Internal Controls: Confirm the effectiveness of the remediation measures for the disclosed significant deficiency in disclosure controls.
- Acquisition Obligations: Review the milestone-based stock and royalty obligations associated with the Lican Developments and Henvil technology acquisitions.
- International Exposure: Monitor foreign currency exchange rate impacts, as international sales grew significantly and are denominated in foreign currencies.